

Review Form 1.6

Journal Name:	International Research Journal of Oncology
Manuscript Number:	Ms_IRJO_86207
Title of the Manuscript:	Emergent new anti PD-1/PD-L1 small molecules for cancer treatment
Type of the Article	Minireview Article

General guideline for Peer Review process:

This journal’s peer review policy states that **NO** manuscript should be rejected only on the basis of ‘**lack of Novelty**’, provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalirjo.com/index.php/IRJO/editorial-policy> )

PART 1: Review Comments

	Reviewer’s comment	Author’s comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	Provide how to select the subjects to deliver ICI in various cases in future clinical trial: 1. especially when we can excellent response. 2. dangerous, greater harm than benefit by delivering ICI (contra-indication) 3. between 1 and 2 Address the subpopulation which may have an exceptional response.	
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments	Useful perspectives.	

PART 2:

	Reviewer’s comment	Author’s comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Haruhiko Sugimura
Department, University & Country	Hamamatsu University School of Medicine, Japan